Roche's James Sabry inks his sec­ond AI deal in back-to-back pacts — this time part­ner­ing Genen­tech with Stan­ford ...

5 years ago
Deals
AI

What about the Ger­man ne­go­ti­a­tion mod­el? Biden steers drug pric­ing de­bate to a show­down

5 years ago
Pharma

En­do pays $658M in a fur­ther bet on col­la­gen-based med­i­cines, buy­ing out long­time bio­phar­ma part­ner

5 years ago
Deals

Su­per-se­cre­tive an­ti-ag­ing biotech Cal­i­co tees up the first vis­i­ble clin­i­cal tri­al of an ex­per­i­men­tal drug. And ...

5 years ago
R&D
Pharma

Covid-19 roundup: Pars­ing Bourla, a top an­a­lyst sees im­proved chances for Pfiz­er vac­cine; Fau­ci: No sur­prise that ...

5 years ago
Coronavirus

RBC's Bri­an Abra­hams holds a mock ad­comm on Bio­gen's iffy ad­u­canum­ab da­ta — and most of these ex­perts don't see a ...

5 years ago
R&D

CAR-plus: Irish biotech re­cruits Kite alum Chris Now­ers to prep dual-tar­get­ing NK cell ther­a­py for the clin­ic

5 years ago
Financing
Cell/Gene Tx

Mer­ck touts new da­ta for Keytru­da com­bos in NSCLC at North Amer­i­can con­fer­ence

5 years ago
R&D

Eu­ro­pean reg­u­la­tors spurn Agios' AML drug Tib­so­vo, un­con­vinced by the same thin PhI da­ta that won over the FDA

5 years ago
R&D
FDA+

News brief­ing: A sweep of CHMP OKs for Al­ny­lam, Kite, No­var­tis and oth­ers; Sanofi's big can­cer play gets OK from UK ...

5 years ago
News Briefing

UCB sketch­es grand plans for new head­quar­ters as it grabs Eli Lil­ly's aban­doned neu­ro R&D cam­pus

5 years ago
Pharma

Af­ter years of short­ages, Mer­ck an­nounces plans for a new fac­to­ry for an old life­sav­ing drug

5 years ago
Outsourcing

FDA of­fi­cials, ex­perts dis­cuss im­pact of Covid-19 on cell and gene ther­a­pies

5 years ago
Cell/Gene Tx
FDA+

Four biotechs and a Matthew Ro­den-led SPAC price IPOs, rais­ing a com­bined $528M

5 years ago
Financing

Ameet Nath­wani re­bounds from Sanofi purge to helm Dew­point; Ali Mor­taza­vi named CEO at e-ther­a­peu­tics

5 years ago
Peer Review

Covid-19 roundup: Can Ab­b­Vie’s dis­ap­point­ing NASH drug ceni­crivi­roc find suc­cess fight­ing cy­tokine storms?; Trump ...

5 years ago
Coronavirus

The prospect of an Oc­to­ber OK large­ly closed, Pfiz­er's Al­bert Bourla promis­es not to sub­mit for EUA un­til No­vem­ber

5 years ago
People
Pharma

WHO says remde­sivir has lit­tle ef­fect in hos­pi­tal­ized Covid-19 — but Gilead calls new da­ta 'in­con­sis­ten­t' with ...

5 years ago
Coronavirus

Gilead feels the heat as close al­ly Gala­pa­gos re­ports a big set­back on one of their top ex­per­i­men­tal drugs

5 years ago
R&D

Fore­site pulls Gem­i­ni Ther­a­peu­tics to Nas­daq in a quick $216M SPAC flip

5 years ago
Deals

News brief­ing: Ot­su­ka’s $886M can­cer drug is now a 3-time los­er in PhI­II; Keytru­da ap­proved for clas­si­cal Hodgkin ...

5 years ago
News Briefing

Eli Lil­ly bags an ear­ly-stage biotech for the neu­ro team — pay­ing $135M cash and of­fer­ing $1B-plus in mile­stones

5 years ago
Deals

No­var­tis vet Dan­ny Bar-Zo­har leaps back in­to R&D, tak­ing over the de­vel­op­ment team at Mer­ck KGaA as Lu­ciano Ros­set­ti ...

5 years ago
People

Covid-19 roundup: Rus­sia ap­proves sec­ond vac­cine, Putin says; Ad­vo­ca­cy groups ask WTO to waive patent rights

5 years ago
Coronavirus
First page Previous page 789790791792793794795 Next page Last page
A service from the Financial Times